BGLC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
76.2K
+233.4%
22.8K
-95.3%
483.8K
-81.0%
2.5M
+12.5%
2.3M
Cost of Revenue
63.2K
+167.3%
23.6K
-95.2%
487.7K
-77.5%
2.2M
+14.5%
1.9M
Gross Profit
13.0K
+1743.3%
-790
+80.2%
-3983
-101.1%
377.7K
+2.6%
368.0K
Operating Expenses
416.4K
-27.0%
570.6K
-47.1%
1.1M
-9.3%
1.2M
+4.4%
1.1M
R&D
13.7K
-5.6%
14.5K
+30.5%
11.1K
-25.4%
14.9K
+18.5%
12.6K
SG&A
334.5K
-12.1%
380.4K
-62.4%
1.0M
+1.4%
997.3K
-11.4%
1.1M
Operating Income
-403401
+29.4%
-571433
+47.2%
-1081855
-33.5%
-810269
-5.3%
-769752
EBITDA
-375336
+30.9%
-543140
+48.4%
-1053425
-34.8%
-781268
-5.3%
-741952
Net Income
-286451
+47.3%
-543575
+47.5%
-1036117
-46.1%
-708991
-15.1%
-616172
EPS (Basic)
$-0.12
+47.8%
$-0.23
+54.9%
$-0.51
-27.5%
$-0.40
-17.6%
$-0.34
EPS (Diluted)
$-0.12
+47.8%
$-0.23
+54.9%
$-0.51
-27.5%
$-0.40
-17.6%
$-0.34
Shares (Diluted)
2.4M
+0.0%
2.4M
+18.7%
2.0M
+13.4%
1.8M
+0.0%
1.8M
BioNexus Gene Lab (BGLC) โ€” Financials